Ixico secures two Huntington's disease clinical trial contracts

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Huntington's disease clinical trials.
The AIM-traded firm said the new contracts included retrospective analysis of data sets for three natural history studies in Huntington's disease with a new large pharma customer, and a multicentre, open-label phase 2 study in Huntington's disease with an existing large pharma customer.

While the contracts to support Huntington's disease clinical trials were not to the same scale as the £10.5m contract announced in April, Ixico said the additional contracts reflected the "strong position" it enjoyed as a neuroscience technology partner in the area.

The contracts did not have a significant impact on management's expectations of performance for the year, but would contribute to its order book.

In addition, the contracts were for early stage clinical trials and, with Ixico noting it had a "strong track record" of following clinical assets through to phase 3, where the contracts generate greater revenues.

"Huntington's disease is a devastating rare neurological condition with unmet medical needs," said chief executive officer Giulio Cerroni.

"IXICO has worked on several Huntington's disease clinical studies since 2007, and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease.

"Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development."

At 1440 BST, shares in Ixico were up 9.44% at 106.16p.